Alprostadil


Thông tin thuốc gốc
Chỉ định và Liều dùng
Intracavernosal
Diagnosis of erectile dysfunction
Adult: 5-20 mcg as a single dose.

Intracavernosal
Erectile dysfunction
Adult: Initially, 2.5 mcg, followed by 5 mcg if there is partial response or 7.5 mcg if there is no response. Subsequent increments of 5-10 mcg are given until suitable dose is reached. Usual dose range: 5-20 mcg. Max: 60 mcg. For neurogenic origin (e.g. spinal cord injury): Initially, 1.25 mcg, followed by 2.5 mcg then 5 mcg, and subsequent increments of 5 mcg until suitable dose at intervals of at least 1 day for responders; for non-responders, a higher dose may be given w/in 1 hr. Max frequency: once daily; 3 times wkly.

Intravenous
Maintenance of patency of ductus arteriosus in neonates with congenital heart disease
Child: Initially, 0.05-0.1 mcg/kg/min via continuous infusion, reduced to the lowest possible dosage that maintains the response. If response is inadequate, may be increased up to 0.4 mcg/kg/min.

Topical/Cutaneous
Erectile dysfunction
Adult: As cream: Initially, 300 mcg is applied to the tip of the penis, may be reduced to 200 mcg if patient cannot tolerate AR. Max frequency: once daily; 2-3 times wkly.

Urethral
Diagnosis of erectile dysfunction
Adult: 500 mcg as a single dose.

Urethral
Erectile dysfunction
Adult: Initially, 250 mcg, may be increased in stepwise manner to 1,000 mcg; or reduced to 125 mcg according to response. Max frequency: twice daily; 7 doses wkly.
Hướng dẫn pha thuốc
Soln for IV inj: Dilute w/ NaCl 0.9% or dextrose 5% inj to provide a soln containing 2-20 mcg/mL, depending on the controlled-infusion device employed and the needs of the neonate. Powd for intracavernosal inj: Dilute w/ bacteriostatic or sterile water according to manufacturer’s instructions.
Chống chỉ định
History of recurrent priapism, sickle cell anaemia or trait, multiple myeloma, leukaemia, thrombocythaemia, polycythaemia, predisposition to venous thrombosis, anatomical penile deformation (e.g. angulation, cavernosal fibrosis, Peyronie’s disease, stenosis of distal urethra, severe hypospadias and curvature, balanitis, acute/chronic urethritis), penile implants. Patient for whom sexual activity is inadvisable (e.g. unstable CV or cerebrovascular conditions). Concomitant use w/ other drugs for erectile dysfunction (e.g. phosphodiesterase type 5 (PDE5) inhibitors, papaverine). Neonates w/ resp distress syndrome. Childn (intracavernosal).
Thận trọng
Patient w/ bleeding tendencies, blood-borne and pulmonary diseases, transient ischaemic attacks, CHD, CHF, history of psychiatric disorder or addiction. Pregnancy (use condom barrier if female partner is or may be pregnant).
Tác dụng không mong muốn
Headache, flushing, hypotension, diarrhoea; pain, haematoma, and ecchymoses at inj site; pain during erection, fibrotic nodules, Peyronie’s disease, priapism. Rarely, penile fibrosis. Apnoea, fever, bradycardia, tachycardia, convulsion, oedema, cardiac arrest, hypokalaemia, disseminated intravascular coagulation, cortical proliferation of long bones (childn).
Thông tin tư vấn bệnh nhân
This drug may cause dizziness, syncope, and hypotension, if affected, do not drive or operate machinery.
Chỉ số theo dõi
Monitor for BP, resp and heart rates, temp, degree of penile pain, duration of erection, adequate detumescence after dosing, and signs of infection.
Quá liều
Symptoms: Hypotension, syncope, dizziness, persistent penile pain, priapism, hypertensive crisis. Management: Symptomatic and supportive treatment. Management of prolonged erection or priapism may include aspiration of cavernosal blood or intracavernosal admin of α-adrenergic agonist (e.g. phenylephrine, epinephrine) or dopamine.
Tương tác
Reduced effect w/ sympathomimetics, decongestants, and appetite suppressants. May enhance the effects of antihypertensives, vasoactive drugs, anticoagulants and platelet aggregation inhibitors.
Potentially Fatal: Enhanced AR, including prolonged erections, w/ PDE5 inhibitors (e.g. sildenafil, tadalafil, vardenafil) and other drugs that induce erection (e.g. papaverine).
Tác dụng
Description:
Mechanism of Action: Alprostadil, a naturally occurring prostaglandin E1, is a vasodilating agent and a platelet aggregation inhibitor. It induces erection by relaxation of the trabecular smooth muscles and dilation of cavernosal arteries, allowing blood flow to the lacunar spaces of the penis. It also relaxes the smooth muscles of the ductus arteriosus.
Onset: Erectile dysfunction: 5-20 min.
Duration: Erectile dysfunction: <1 hr.
Pharmacokinetics:
Absorption: Time to peak plasma concentration: 30-60 min (intracavernosal); approx 16 min (urethral).
Distribution: Plasma protein binding: 81%, mainly to albumin; 55% to α-globulin IV-4 fraction.
Metabolism: Metabolised (approx 70-80%) in a single pass through the lungs via β- and omega-oxidation into 13,14-dihydro-PGE1, 15-keto-PGE1, and 15-keto-13,14-dihydro-PGE1 (IV).
Excretion: Via urine (90% as metabolites) and faeces. Elimination half-life: 0.5-10 min.
Đặc tính

Chemical Structure Image
Alprostadil

Source: National Center for Biotechnology Information. PubChem Database. Alprostadil, CID=5280723, https://pubchem.ncbi.nlm.nih.gov/compound/Alprostadil (accessed on Jan. 20, 2020)

Bảo quản
Soln for IV inj/cream/urethral stick: Store between 2-8°C. Do not freeze. Powd for intracavernosal inj: Store below 25°C (5, 10, 20 mcg); 2-8°C (40mcg).
Phân loại MIMS
Thuốc trị rối loạn cương và rối loạn xuất tinh / Thuốc giãn mạch ngoại biên & thuốc hoạt hóa não
Phân loại ATC
G04BE01 - alprostadil ; Belongs to the class of drugs used in erectile dysfunction.
C01EA01 - alprostadil ; Belongs to the class of prostaglandins used in cardiac therapy.
Tài liệu tham khảo
Alprostadil Injection, Solution, Concentrate (Teva Parenteral Medicines, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 8/23/2016.

Anon. Alprostadil. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 8/23/2016.

Buckingham R (ed). Alprostadil. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 8/23/2016.

Caverject Injection, Powder, Lyophilized, for Solution (Pharmacia and Upjohn Company LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 8/23/2016.

Joint Formulary Committee. Alprostadil. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 8/23/2016.

McEvoy GK, Snow EK, Miller J et al (eds). Alprostadil. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 8/23/2016.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Alprostadil từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2024 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
  • Alprostapint
  • Caverject
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in